Moderna announces dozing of first patient with its mRNA1273 vaccine
The pharmaceutical company, Moderna, has been developing a vaccine for the treatment of COVID-19. The vaccine is an mRNA-1273 is developed by scientist at NAID, in collaboration with Moderna, and the manufacturing of the vaccine for Phase I clinical trial has been supported by Coalition for Epidemic Preparedness Innovations (CEPI).
The company has announced that the first patient has been dozed with the vaccine to protect against COVID-19 due to SARS-CoV-2 virus. The Phase I study is being conducted by the National Institutes of Health (NIH) under its own Investigational New Drug (IND) applicati...
